Patient baseline characteristics, admission, treatment, and discharge metrics
| Case | Age (yr)/Sex | Length of Stay (Days) | NIHSS (Admission/Discharge) | IA Verapamil (No. of Cycles/Total Amount) | Follow-Up Interval (Weeks) | Follow-Up Imaging Results or Clinical Examination |
|---|---|---|---|---|---|---|
| 1 | 43/F | 19 | 16/1 | 5/120 mg | 16 | Resolution of vasoconstriction |
| 2 | 43/F | 17 | 0/0 | 1/30 mg | 1 | Near-complete resolution of vasoconstriction |
| 3 | 25/M | 14 | 2/0 | 2/40 mg, Balloon angioplasty | 5 | Resolution of vasoconstriction |
| 4 | 43/F | 15 | 4/2 | 2/55 mg | 12 | mRS 1, cognitive delay, NIHSS 0 |
| 5 | 35/F | 11 | 2/0 | 1/20 mg | 1 | mRS 0 |
| 6 | 25/F | 3 | 0/0 | 1/15 mg | – | Lost to follow-up |
| 7 | 27/F | 6 | 4/1 | 1/12.5 mg | 1 | Resolution of vasoconstriction |
| 8 | 33/M | 4 | 0/0 | 1/10 mg | – | Lost to follow-up |
| 9 | 69/F | 30 | 10/4 | 3/60 mg | 52 | Died from multiple myeloma complications |
| 10 | 52/F | 11 | 0/0 | 1/10 mg | 6 | Resolution of vasoconstriction |
| 11 | 25/F | 21 | 4/0 | 6/180 mg | – | Lost to follow-up |
Note:—– indicates that no clinical or imaging follow-up was available.